Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GVK Biosciences has entered into a research agreement with Wyeth Pharmaceuticals, a division of Wyeth, to discover drug candidates focused on pre-defined discovery targets.
Subscribe to our email newsletter
Under the agreement, GVK Bio will receive an initial payment and will be eligible for success-based milestone payments. GVK Bio will be responsible for identifying drug candidates, which will be transferred to Wyeth to advance these compounds towards clinical studies.
GVK Bio will utilize in-house capabilities in discovery chemistry, informatics, biology and ADME to advance this program.
Sanjay Reddy, managing director of GVK Bio, said: “This research agreement expands our work together and builds on GVK Bio’s core strengths. This agreement further validates India’s capability to do innovative research along with leading pharmaceutical and biotech companies.”